No Detail Found!

Non-invasive Screening of Metabolic Associated Fatty Liver Disease and A ecting Factors in Primary Care

Author(s)
Idil Ceren Balci Department of Family Medicine, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Kartal, Istanbul
Nazli Haciagaoglu Department of Family Medicine, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Kartal, Istanbul
Can Oner Department of Family Medicine, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Kartal, Istanbul
Huseyin Cetin Department of Family Medicine, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Kartal, Istanbul
Engin Ersin Simsek Department of Family Medicine, University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Kartal, Istanbul
Abstract
Objective: To identify the presence of MAFLD (metabolic associated fatty liver disease) with some non-invasive screening methods and the factors a ecting in patients with metabolic dysfunction. Study Design: A cross-sectional study. Place and Duration of the Study: University of Health Sciences, Kartal Dr. Lut Kirdar City Hospital, Istanbul, Turkiye, from March to June 2021. Methodology: This study included 233 participants with metabolic disease over the age of 18 who applied to family medicine clinics. The participants' sociodemographic data, chronic disease status, biochemical parameters, waist circumference, weight, height, body mass index, and presence of steatosis by ultrasonography were recorded. The risk of developing hepatic brosis and steatosis was calculated with the non-alcoholic fatty liver disease liver fat score (NAFLD-LFS), hepatic steatosis index (HSI), fatty liver index (FLI), brosis-4 index (FIB-4), NAFLD brosis score (NAFLD-FS), and aspartate aminotransaminase to platelet ratio index (APRI). The conclusions were evaluated with SPSS. Results: According to the diagnostic criteria, MAFLD was detected in 58.4% of the participants. Statistically signi cant di erence was found between FLI, HSI, NAFLD-LFS and MAFLD (p<0.001). According to the steatosis index risk groups of the participants, 64.4% 89.7% were found to be high-risk. Steatosis was con rmed by ultrasonography in 63.6% - 77.8% of those at high-risk for index steatosis. The statistically signi cant di erence was found between hypertension, diabetes mellitus, hyperlipidemia, metabolic syndrome, obesity, and MAFLD (p=0.039, p<0.001, p<0.001, p<0.001, and p=0.011, respectively). Conclusion: Using non-invasive screening methods for steatosis can be clinically useful in detecting patients at risk for steatosis, and these methods are applicable in predicting MAFLD.
Publication Details
Page(s) 390-395
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 4, Year: 2023

Request the full text from PASTIC

Keywords
NAFLD, Steatosis, Fatty liver 1ndex, Hepatic steatosis index, MAFLD
0

Citations

0

Downloads

42

Views